Figures & data
Figure 2. Expression of circulating miR-29b and VEGFA in glioma cases and healthy controls. (A) Expression of circulating miR-29b in stages I and II, stages III and IV glioma cases and healthy controls. (B) Expression of circulating VEGFA in stages I and II, stages III and IV glioma cases and healthy controls.
![Figure 2. Expression of circulating miR-29b and VEGFA in glioma cases and healthy controls. (A) Expression of circulating miR-29b in stages I and II, stages III and IV glioma cases and healthy controls. (B) Expression of circulating VEGFA in stages I and II, stages III and IV glioma cases and healthy controls.](/cms/asset/df9f2384-2031-40c2-a7e8-1a4e804a39f7/ianb_a_1111237_f0002_b.jpg)
Table I. Correlation of serum miR-29b and VEGFA expression with clinicopathological features of glioma.
Figure 5. The circulating miR-29b and VEGFA level of pre- and post-operation of the glioma patients.
![Figure 5. The circulating miR-29b and VEGFA level of pre- and post-operation of the glioma patients.](/cms/asset/8b71c4aa-26f0-4cfa-b39c-50c41447882a/ianb_a_1111237_f0005_b.jpg)
Table II. Clinicopathological features and serum biomarkers as risk factors of glioma.